Nasdaq:US$18.88 (+0.85) | HKEX:HK$29.95 (+0.65) | AIM:£2.97 (-0.03)
News & Presentations
Previous Article   |   Next Article
Presentations | 18 Apr 2023

AACR 2023: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies